Suven Life Sciences Ltd. — Investor Relations & Filings
Suven Life Sciences Ltd. focuses on the discovery and development of novel therapeutic agents for Central Nervous System (CNS) disorders. The company specializes in New Chemical Entity (NCE) research, targeting unmet medical needs in conditions such as Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease, and depression. Its clinical pipeline includes lead candidates like Masupirdine (SUVN-502) for cognitive impairment and Samelisant (SUVN-G3031) for narcolepsy. Suven utilizes an integrated drug discovery platform and maintains a significant global intellectual property portfolio. The organization provides drug discovery and development support services, leveraging expertise in medicinal chemistry and pharmacology to advance internal programs and collaborative research initiatives.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Copy of Newspaper Publication | 2026-04-23 | English | |
| Price movement | 2026-04-08 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-27 | English | |
| Outcome of Board Meeting | 2026-03-06 | English | |
| Allotment of Securities | 2026-03-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42171737 | Copy of Newspaper Publication | 2026-04-23 | English | ||
| 42187106 | Price movement | 2026-04-08 | English | ||
| 42208254 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | ||
| 42223422 | Trading Window | 2026-03-27 | English | ||
| 42197228 | Outcome of Board Meeting | 2026-03-06 | English | ||
| 42197303 | Allotment of Securities | 2026-03-06 | English | ||
| 42168398 | Copy of Newspaper Publication | 2026-02-19 | English | ||
| 42295958 | Price movement | 2026-02-06 | English | ||
| 42221508 | Monitoring Agency Report | 2026-02-03 | English | ||
| 42258219 | Copy of Newspaper Publication | 2026-01-30 | English | ||
| 42179002 | Appointment | 2026-01-29 | English | ||
| 42179326 | Resignation | 2026-01-29 | English | ||
| 42179815 | Outcome of Board Meeting | 2026-01-29 | English | ||
| 42180211 | Outcome of Board Meeting | 2026-01-29 | English | ||
| 42229887 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-01-06 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Bonus BioGroup Ltd.
A clinical-stage biotech firm developing cell therapy and t…
|
BONS | IL | Professional, scientific and te… |
|
BPH GLOBAL LTD
Biotech firm focused on plant-based health products and fun…
|
BP8 | AU | Professional, scientific and te… |
|
BRAIN Biotech AG
Develops enzymes and microorganisms for the food, chemical,…
|
BNN | DE | Professional, scientific and te… |
|
BriaCell Therapeutics Corp.
Clinical-stage immuno-oncology company developing cellular …
|
BCTX | CA | Professional, scientific and te… |
|
Bright Minds Biosciences Inc.
Developing innovative serotonin-based drugs for neurologica…
|
DRUG | CA | Professional, scientific and te… |
|
BRIM Biotechnology, Inc.
Develops therapies for ophthalmology and degenerative disea…
|
6885 | TW | Professional, scientific and te… |
|
BSF ENTERPRISE PLC
Develops cell-based solutions for cultivated meat, leather,…
|
BSFA | GB | Professional, scientific and te… |
|
BullFrog AI Holdings, Inc.
A technology company applying AI and machine learning to dr…
|
BFRG | US | Professional, scientific and te… |
|
Burning Rock Biotech Ltd
A global diagnostics company specializing in precision onco…
|
BNR | US | Professional, scientific and te… |
|
Cabaletta Bio, Inc.
Develops engineered T cell therapies for B cell-mediated au…
|
CABA | US | Professional, scientific and te… |
Suven Life Sciences Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61491/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61491 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61491 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61491 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61491}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Suven Life Sciences Ltd. (id: 61491)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.